Neuroprotective effect of dopamine agonists;Neuroprotekcyjne działanie agonistów dopaminy

Neurologia i Neurochirurgia Polska

Volumn 41, Issue 2 SUPPL. 1, 2007, Pages

  Szczudlik, Andrzej ^a   Rudzińska, Monika ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

Author keywords

Dopamine agonists; Neuroprotection; Parkinson's disease

Indexed keywords

6 FLUORODOPA; ALPHA TOCOPHEROL; BIOLOGICAL MARKER; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; SELEGILINE;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL LOSS; CLINICAL TRIAL; DISEASE COURSE; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL MODEL; HUMAN; NERVE DEGENERATION; NEUROIMAGING; NEUROPROTECTION; OUTCOME ASSESSMENT; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBTHALAMIC NUCLEUS;

ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; CORPUS STRIATUM; DOPAMINE AGONISTS; HUMANS; LEVODOPA; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PUTAMEN; SUBTHALAMIC NUCLEUS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34248538130     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Schapira A.H. Neuroprotection in PD - a role for dopamine agonists? Neurology 2003; 61 (supl. 3): 34-42.
2. Koller W. Perspectives in neuroprotection in Parkinson's disease. W: Mizuno Y. [red.]. Neuroprotection and neurodegeneration in Parkinson's disease. Royal Society of Medicine Press Ltd., London 2000, ss. 27-32.
3. Poewe W. The reed for neuroprotective therapies in Parkinson's disease: a clinical perspective. Neurology 2006; 66 (supl. 4): 2-9.
4. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-2301.
5. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321: 1364-1371.
6. Parkinson Study Group. Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328: 176-183.
7. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996; 39: 29-36.
8. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996; 39: 37-45.
9. Hauser R.A., Zesiewicz T.A. Clinical trials aimed at detecting neuroprotection in Parkinson's disease. Neurology 2006; 66 (suppl. 4): S58-68.
10. Olanow C.W, Hauser R.A., Gauger L. i wsp. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995; 38: 771-777.
11. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson's disease. Arch Neurol 2004; 59: 1937-1943.
12. Fahn S., Oakes D., Shoulson I. i wsp. Levodopa and the progression of Parkinson disease. N Engl J Med 2002; 351: 2498-2508.
13. Schapira A.H. Neuroprotection and dopamine agonists. Neurology 2002; 58 (supl. 1): 9-18.
14. Piercey M., Camacho-Ochoa M., Smith M. Functional role of dopamine receptor subtypes. Clin Neuropharmacol 1995; 18: 34-42.
15. Giasson B.I., Duda J.E., Murray I.V. i wsp. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000; 290: 985-989.
16. O'Neill M.J., Hicks C.A., Ward M.A. i wsp. Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia. Eur J Pharmacol 1998; 352: 37-46.
17. Liu X.H., Kato K., Chen T. i wsp. Bromocriptine protects against delayed neuronal death of hippocampal neurons following cerebral ischemia in the gerbil. J Neurol Sci 1995; 129: 9-14.
18. Hall ED., Andrus P.K., Oostveen J.A. i wsp. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res 1996; 742: 80-88.
19. Le W.D., Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging 2001; 18: 389-396.
20. Muralikrishnan D., Mohanakumar K.P. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 1998; 12: 905-912.
21. Asanuma M., Ogawa N., Nishibayashi S. i wsp. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain. Arch Int Pharmacodyn Ther 1995; 329: 221-230.
22. Carvey P.M., Pieri S., Ling Z.D. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 1997; 104: 209-228.
23. Takashima H., Tsujihata M., Kishikawa M. i wsp. Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D (2) receptors. Exp Neurol 1999; 159: 98-104.
24. Iida M., Miyazaki I., Tanaka K. i wsp. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res1999; 838: 51-59.
25. Gassen M., Gross A., Youdim M.B. Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Mov Disord 1998; 13: 242-248.
26. Dennis J., Khan S., Cassarino D. i wsp. Inhibition of cell death pathways by S (-) and R (+) pramipexole in pharmacological models of Parkinson's and Alzheimer's disease. Soc Neurosci Abst 1999; 29: 539.
27. Whone A.L., Watts R.L., Stoessl A.J. i wsp. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93-101.
28. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000; 284: 1931-1938.
29. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa in Parkinson disease progression. JAMA 2002; 287: 1653-1661.